Alphatec (ATEC) Stock Price, News & Analysis

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 12 month price targets for Alphatec's stock. Their ATEC share price targets range from $17.00 to $32.00. On average, they predict the company's share price to reach $23.63 in the next year. This suggests a possible upside of 88.8% from the stock's current price.
View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts.

Alphatec's stock was trading at $15.11 at the beginning of the year. Since then, ATEC stock has decreased by 17.2% and is now trading at $12.51.
View the best growth stocks for 2024 here.

Alphatec saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 12,360,000 shares, an increase of 12.2% from the March 15th total of 11,020,000 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is presently 7.3 days.
View Alphatec's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ATEC earnings forecast.

Alphatec Holdings, Inc. (NASDAQ:ATEC) released its quarterly earnings results on Tuesday, February, 27th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.09. The medical technology company earned $138 million during the quarter, compared to the consensus estimate of $131.90 million. The firm's revenue was up 30.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.33) EPS.

ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).Invesco Nasdaq Future Gen 200 ETF (QQQS).

Alphatec issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $595.0 million-$595.0 million, compared to the consensus revenue estimate of $574.7 million.

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX).

Alphatec's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.10%) and Newton One Investments LLC (0.00%). Insiders that own company stock include Craig E Hunsaker, David H Mowry, David M Demski, David R Pelizzon, David Sponsel, Elizabeth Ann Altman, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jennifer N Pritzker, Jennifer N Pritzker, John Todd Koning, L-5 Healthcare Partners, Llc, Mortimer Berkowitz III, Patrick Miles, Paul Segal, Quentin S Blackford, Scott Lish and Tyson Eliot Marshall.
View institutional ownership trends.

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.